Trulicity Pre-Surgery Hold Window: When to Stop Dulaglutide Before an Operation

Why the Pre-Surgery Hold Window Matters for Dulaglutide

Dulaglutide is a once-weekly GLP-1 receptor agonist that significantly slows gastric emptying as part of its glucose-lowering mechanism. That effect does not disappear when a patient follows a standard nil-per-os (NPO) instruction the night before surgery. Residual food or liquid can remain in the stomach even after 8 hours of fasting, placing patients at real risk of aspiration during induction of anesthesia.

The American Society of Anesthesiologists (ASA) issued a consensus statement in 2023 specifically addressing this risk class. The guidance states that, for patients on weekly GLP-1 agonists, the drug should be held for a full dosing interval before elective procedures requiring general or neuraxial anesthesia. For dulaglutide, that interval is 7 days. American Society of Anesthesiologists, 2023 Consensus-Based Guidance on Preoperative Management of GLP-1 Receptor Agonists.

Gastric Emptying and the Aspiration Pathway

GLP-1 receptors on enteric neurons and smooth muscle slow the rate at which the stomach empties into the duodenum. In clinical studies, dulaglutide at 1.5 mg reduced postprandial gastric emptying rates measurably compared with placebo, an effect that persists throughout the dosing week. Nauck MA et al. Effects of subcutaneous glucagon-like peptide 1 infusion in type 1 diabetic patients, Diabetes Care.

Pulmonary aspiration of gastric contents during anesthesia carries a mortality risk of roughly 5% per aspiration event and a morbidity risk considerably higher. Even a small volume of acidic gastric fluid can cause aspiration pneumonitis. The standard NPO guideline (solids for 6 to 8 hours, clear liquids for 2 hours) was developed for patients with normal gastric motility. Patients on GLP-1 agonists may not meet that assumption.

Point-of-Care Ultrasound as a Safety Net

When a patient arrives for urgent surgery and has taken dulaglutide within the past 7 days, anesthesiologists may use gastric point-of-care ultrasound (POCUS) to assess antral cross-sectional area. An antral area above approximately 340 mm² in the right lateral decubitus position suggests a non-empty stomach and warrants rapid-sequence induction or postponement of the case if clinically feasible. Van de Putte P, Perlas A. Ultrasound assessment of gastric content and volume. Br J Anaesth. 2011. This approach does not replace the hold window but provides real-time information when the history is unclear.

Dulaglutide Pharmacokinetics: Why 7 Days Is the Minimum

Half-Life and Steady-State Behavior

Dulaglutide has a terminal elimination half-life of approximately 5 days, which is longer than most oral GLP-1 agents and longer than daily injectable liraglutide (half-life roughly 13 hours). After a single 1.5 mg subcutaneous dose, peak plasma concentration occurs at 24 to 72 hours. Steady state is reached after 2 to 3 weeks of weekly dosing. Glaesner W et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010.

Holding for 7 days represents one half-life of reduction from steady-state plasma levels, not complete elimination. Full pharmacokinetic washout would require approximately 25 days. The 7-day recommendation is therefore a pragmatic clinical compromise based on the balance between aspiration risk reduction and the metabolic risk of discontinuing the drug longer than necessary.

Why Daily GLP-1 Agents Follow a Different Rule

The ASA 2023 guidance recommends holding daily GLP-1 agonists (such as liraglutide) for only 1 day before surgery, not 7. The distinction matters because dulaglutide's weekly dosing means that the most recent dose may have been administered just 1 to 2 days before the planned procedure. Holding for 7 days ensures the patient has missed a full dosing cycle and that plasma levels have declined substantially, even if not to zero. Prescribers managing a transition plan should document the date of the patient's last injection explicitly in the surgical pre-assessment.

The REWIND Trial: Cardiovascular Context for Dulaglutide Use

Trial Design and Primary Outcome

REWIND (Researching Cardiovascular Events With a Weekly Incretin in Diabetes) enrolled 9,901 adults with type 2 diabetes at high cardiovascular risk or with established cardiovascular disease. Participants were randomized to dulaglutide 1.5 mg once weekly or placebo and followed for a median of 5.4 years. The primary endpoint was the first occurrence of a major adverse cardiovascular event (MACE): nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular or undetermined causes. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019.

REWIND showed a 12% relative risk reduction in MACE (HR 0.88, 95% CI 0.79 to 0.99, P<0.05), with the benefit driven largely by a reduction in nonfatal stroke. The trial included a notably broad population: 69% of participants had no prior cardiovascular event at enrollment, making REWIND distinctive among GLP-1 cardiovascular outcome trials. Gerstein HC et al. Lancet. 2019.

What REWIND Means for the Perioperative Decision

The cardiovascular benefit documented in REWIND underscores that dulaglutide is not a drug to discontinue casually or for longer than necessary. Patients with type 2 diabetes who undergo major surgery already face elevated perioperative cardiovascular risk. Holding dulaglutide for exactly 7 days, rather than weeks, limits the window of lost cardioprotective exposure. The prescribing team and surgeon should coordinate to ensure the hold is as short as the surgical timeline permits.

Perioperative Blood Glucose Management When Dulaglutide Is Held

Expected Glycemic Changes After Discontinuation

When dulaglutide is held, patients lose three glucose-lowering mechanisms simultaneously: GLP-1-mediated insulin secretion enhancement, glucagon suppression, and delayed gastric absorption. Blood glucose may rise, particularly postprandially, within 2 to 4 days of the missed dose. Patients on dulaglutide as monotherapy or in combination with metformin only (no sulfonylurea or insulin) are at low intrinsic hypoglycemia risk but may see fasting glucose climb by 20 to 40 mg/dL above their usual baseline.

The Society for Perioperative Assessment and Quality Improvement (SPAQI) recommends a target intraoperative glucose of 140 to 180 mg/dL for most surgical patients with diabetes, with point-of-care glucose checks every 1 to 2 hours during procedures lasting more than 2 hours. Duggan EW et al. Revisiting Perioperative Fasting Recommendations: SPAQI Consensus Statement. Anesth Analg. 2017.

Insulin Adjustment During the Hold Period

Patients who take basal insulin alongside dulaglutide may need a modest upward adjustment of their basal dose during the 7-day hold, particularly if HbA1c is above 8.0% (64 mmol/mol) at baseline. A common clinical approach is to increase basal insulin by 10 to 20% during the hold and to check fasting glucose daily. This adjustment should be individualized; patients with tighter baseline control (HbA1c 6.5 to 7.5%) may not require any change.

Sulfonylureas co-prescribed with dulaglutide pose a hypoglycemia risk on the day of surgery independent of the GLP-1 hold. Standard practice is to hold sulfonylureas on the morning of surgery regardless of dulaglutide status. ADA Standards of Medical Care in Diabetes 2024, Section 16: Diabetes Care in the Hospital.

Continuous Glucose Monitoring in the Perioperative Window

Patients using a continuous glucose monitor (CGM) during the hold period have an advantage: trend arrows and time-in-range data give a real picture of how much glycemic drift is occurring without dulaglutide on board. The Endocrine Society's 2022 clinical practice guideline on inpatient glycemic management supports CGM use in selected hospitalized patients, though it notes that CGM values should be verified with point-of-care glucose meters before treatment decisions in the OR. Umpierrez GE et al. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes. 2022.

Practical Steps for Prescribers: The 7-Day Hold Protocol

A clear written protocol reduces the chance of a patient taking their weekly injection too close to surgery. The following stepwise approach reflects current ASA and ADA guidance and can be adapted to a clinic's pre-surgical workflow.

Step 1: Identify the Surgery Date and Work Backward

Confirm the exact date of surgery with the surgical team. Count back 7 full days. That is the date of the patient's last permitted dulaglutide injection before the procedure. If the patient's usual injection day falls within 7 days of surgery, they skip that dose entirely. If it falls on day 8 or beyond, they may take their usual dose and then hold.

Document the date of the last injection in the pre-anesthesia assessment form. Anesthesia providers consistently report that this information is missing or unclear in a significant proportion of GLP-1 prescriptions reviewed pre-operatively. Clear documentation takes less than 30 seconds and prevents the need for last-minute case postponements.

Step 2: Notify the Patient Explicitly in Writing

Verbal instructions alone are not sufficient. A written note in the patient's after-visit summary, a secure message, or a pharmacy counseling note should state: "Do not inject your Trulicity pen after [specific date]. Your next injection after surgery will be on [specific date] once you are eating normally."

Patients sometimes assume that because Trulicity is a diabetes medication, they should never stop it without insulin. Clear language eliminates that confusion.

Step 3: Coordinate With the Surgical and Anesthesia Teams

The prescribing clinician should communicate the dulaglutide hold to both the surgeon's office and the anesthesia pre-assessment team at the time of surgical referral. A brief note in the referral letter stating "patient is on dulaglutide 1.5 mg weekly, last dose planned for [date], 7 days pre-op" satisfies the ASA's documentation expectation and reduces the risk of the anesthesiologist discovering the medication for the first time on the day of surgery.

Step 4: Plan the Restart

Dulaglutide can generally be restarted once the patient tolerates oral intake without nausea and bowel function has returned. For most elective abdominal or orthopedic procedures, this is 1 to 3 days post-operatively. For major GI surgery (bariatric procedures, bowel resection), the restart timing should be discussed with the surgical team, as gut motility recovery may take longer and GLP-1-related nausea could complicate the post-surgical course.

Special Populations: Obesity, Bariatric Surgery, and Off-Label GLP-1 Use

Dulaglutide is approved only for type 2 diabetes in the United States, unlike semaglutide 2.4 mg (Wegovy), which carries an FDA approval for chronic weight management. However, dulaglutide is prescribed off-label for obesity in some clinical settings. Patients taking dulaglutide for weight management who are scheduled for bariatric surgery need the same 7-day hold, plus an explicit post-operative plan that accounts for the dramatic changes in GI anatomy and absorption that follow procedures such as Roux-en-Y gastric bypass. FDA prescribing information for Trulicity (dulaglutide). Accessdata.fda.gov.

For patients undergoing endoscopy (upper GI endoscopy, colonoscopy), the ASA guidance applies if the procedure requires moderate or deep sedation. The same 7-day hold is recommended. Minor procedures under local anesthesia alone do not require a dulaglutide hold, though this should be confirmed with the proceduralist.

Urgent and Emergency Surgery: When the Hold Window Cannot Be Met

Not every surgery is elective. When a patient on dulaglutide requires urgent or emergent surgery and the 7-day hold has not been completed, the anesthesia team should be informed of the exact date of the last injection and the dose. Gastric POCUS assessment of antral volume should be performed if the patient's clinical condition permits. Rapid-sequence induction (RSI) with cricoid pressure should be considered for any patient with a suspected non-empty stomach, regardless of reported fasting duration. El-Orbany M, Connolly LA. Rapid Sequence Induction and Intubation: Current Controversy. Anesth Analg. 2010.

The anesthesiologist carries the ultimate clinical judgment on induction technique. The prescribing clinician's role in an emergency is to provide accurate medication history as quickly as possible, including the brand name, dose, and date of last injection.

Summary of Key Numbers for Clinical Reference

| Parameter | Value | |---|---| | Dulaglutide half-life | ~5 days | | Recommended hold before elective surgery | 7 days (1 dosing cycle) | | REWIND MACE relative risk reduction | 12% (HR 0.88) | | REWIND trial population | N=9,901, median follow-up 5.4 years | | Target intraoperative glucose (SPAQI) | 140 to 180 mg/dL | | Gastric antral area threshold for POCUS concern | ~340 mm² (right lateral decubitus) | | Daily GLP-1 agonist hold duration (ASA 2023) | 1 day |